- $459.06m
- $167.52m
- $0.04m
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Altimmune Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Nebius Group, Lumentum Holdings
Altimmune rises on smaller-than-expected quarterly loss
Altimmune posts smaller-than-expected Q2 net loss per share
Altimmune Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Altimmune Initiates PERFORMA Phase 3 Trial Of Pemvidutide In Patients With Mash
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
U.S. STOCKS ON THE MOVE-Visa, CMS Energy, Ecolab
U.S. STOCKS ON THE MOVE-Visa, CMS Energy, Ecolab
U.S. STOCKS ON THE MOVE-American Tower, Xylem, Core Scientific
Altimmune jumps as experimental obesity drug shows benefit in alcohol use disorder study
Altimmune drug cuts heavy drinking in mid-stage trial for alcohol use disorder (updated)
Altimmune's drug meets main goal of mid-stage study for alcohol use disorder
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up